Quest diagnostics logo

News and events

Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus’ TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma

Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of best-in-class personalized MRD technology (Haystack MRD™), has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development

Read More >

Quest Diagnostics Completes Acquisition of Haystack Oncology, Adding Sensitive MRD Liquid Biopsy Technology to Cancer Diagnostics Portfolio

SECAUCUS, N.J., June 21, 2023 /PRNewswire/ — Quest Diagnostics (NYSE:DGX), the nation’s leading provider of diagnostic information services, today announced that it has completed its previously announced acquisition of Haystack Oncology. Haystack Oncology has developed a highly sensitive minimal-residual disease (MRD) testing technology, based

Read More >

Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology for Improving Personalized Cancer Care to Oncology Portfolio

SOURCE Quest Diagnostics Goal to improve patient outcomes through early, accurate detection of residual or recurring cancer Haystack’s highly sensitive minimal-residual disease cancer-detection technology to be combined with Quest’s oncology, genomics and pathology expertise and scale, including solid tumor sequencing,

Read More >

Precision Medicine World Conference 2023 Silicon Valley

Haystack’s co-founder and Chief Innovation Officer, Josh Cohen, will be participating in a panel discussion at the upcoming Precision Medicine World Conference (PMWC) in Silicon Valey, CA. The panel, “Liquid Biopsy for Minimal Residual Disease,” will take place on January 26 and

Read More >

Subscribe for updates

No spam, notifications only about new products, updates.
Recent events

American Association for Cancer Research 2024

Haystack MRD™ by Quest Diagnostics® will be attending the 2024 American Association for Cancer Research (AACR) annual meeting taking place April 5–10, 2024 in San Diego, CA. The AACR annual

ASCO Gastrointestinal Cancers Symposium 2024

Haystack Oncology, a Quest Diagnostics® company, will be attending the 2024 American Society of Clinical Oncology Gastrointestinal Cancers symposium (ASCO GI), which will be held January 18–20, 2024, in San

Follow us on social media

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Visit Johns Hopkins School of Medicine to learn more.
Visit Johns Hopkins School of Medicine to learn more.
Visit Johns Hopkins School of Medicine to learn more.